Logo

SRRK

Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation • NASDAQ
$44.06 ▲ 2.11% (+0.91)
Market Cap $4.49 B
52w High $46.98
52w Low $22.71
Dividend Yield 0%
P/E -13.99
Volume 690.12K
Outstanding Shares 102.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $103.127M ▼ $-102.22M ▲ 0% $-0.9 ▲ $-100.463M ▲
Q2-2025 $0 $111.692M ▲ $-110.031M ▼ 0% $-0.98 ▼ $-108.408M ▼
Q1-2025 $0 $76.697M ▲ $-74.723M ▼ 0% $-0.67 $-76.697M ▼
Q4-2024 $0 $68.962M ▲ $-66.454M ▼ 0% $-0.67 ▼ $-66.059M ▼
Q3-2024 $0 $64.334M $-64.479M 0% $-0.66 $-64.334M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $369.63M ▲ $411.718M ▲ $166.723M ▲ $244.995M ▲
Q2-2025 $295.013M ▼ $340.045M ▼ $106.752M ▲ $233.293M ▼
Q1-2025 $364.375M ▼ $407.553M ▼ $95.22M ▼ $312.333M ▼
Q4-2024 $437.278M ▲ $474.922M ▲ $106.288M ▲ $368.634M ▲
Q3-2024 $139.065M $179.133M $99.937M $79.196M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-102.22M ▲ $-68.923M ▲ $59.699M ▼ $144.469M ▲ $135.245M ▲ $-69.007M ▲
Q2-2025 $-110.031M ▼ $-76.941M ▲ $85.466M ▲ $6.474M ▲ $14.999M ▲ $-77.156M ▲
Q1-2025 $-74.723M ▼ $-78.675M ▼ $34.554M ▲ $4.169M ▼ $-39.952M ▼ $-78.946M ▼
Q4-2024 $-66.454M ▼ $-49.513M ▲ $-195.37M ▼ $346.37M ▲ $101.487M ▲ $-49.535M ▲
Q3-2024 $-64.479M $-52.455M $35.308M $166K $-16.981M $-52.486M

Five-Year Company Overview

Income Statement

Income Statement Scholar Rock is still very much a research-focused biotech with essentially no product revenue yet. The income statement shows recurring, sizeable operating losses each year, driven mainly by R&D and supporting costs. Losses have grown more recently, which is typical as a company moves into larger, late‑stage clinical trials and begins preparing for potential commercialization. Earnings per share have been negative throughout, so the story here is still about investing heavily ahead of any meaningful sales rather than generating profits.

Balance Sheet

Balance Sheet The balance sheet shows a company that is asset‑light but reasonably well capitalized for its stage. Cash makes up a large share of total assets, which is what you want to see for a clinical‑stage biotech. Debt is present but not dominant, and shareholders’ equity remains positive and has grown in recent years, suggesting successful capital raising. Overall, the balance sheet looks geared toward funding R&D and upcoming launch preparation rather than owning physical assets or infrastructure.

Cash Flow

Cash Flow Cash flow is consistently negative from operating activities, reflecting ongoing clinical development and no commercial revenue yet. Free cash flow tracks closely with operating cash flow, because capital spending on equipment and facilities is modest. This pattern is standard for a pipeline‑driven biotech: the company regularly consumes cash and must occasionally replenish it through equity or partnership funding. The external commentary that cash is expected to last into the latter part of the decade suggests management has planned ahead for this burn, but long‑term, future approvals or new financing will still be important.

Competitive Edge

Competitive Edge Scholar Rock’s competitive position rests on a focused and differentiated scientific approach. By targeting the inactive forms of growth factors and concentrating on muscle‑directed therapies, the company is aiming at an unmet need that existing SMA drugs do not fully address. The lead candidate, designed to improve muscle strength on top of current standards of care, could be complementary rather than directly head‑to‑head with incumbents, which helps its positioning. Its specialized know‑how around the TGF‑beta family, an expanding patent estate, and interest from collaborators all support a defensible niche. At the same time, the company faces large, well‑funded competitors in neuromuscular disease and oncology, and its dependence on a small number of key programs means setbacks in those areas could weigh heavily on its overall standing.

Innovation and R&D

Innovation and R&D Innovation is the core of Scholar Rock’s value proposition. The company has built a proprietary platform around growth factor modulation, with deep expertise in a complex biology area that many others have struggled to drug safely. The late‑stage SMA program, now under regulatory review, provides real‑world validation of this science and is the centerpiece of its near‑term prospects. Beyond that, the pipeline spans cancer, obesity, and other conditions, showing that the technology can be applied more broadly. This breadth is a strength but also requires disciplined R&D prioritization so that resources are focused on the most promising, value‑creating programs.

Summary

Scholar Rock is a classic high‑risk, high‑potential clinical‑stage biotech: no commercial revenue yet, significant and rising R&D spending, and a balance sheet currently built to fund several more years of development. The company’s story is dominated by one pivotal asset in SMA, which, if approved, could transform it into a commercial enterprise and validate its broader platform. Its scientific approach and pipeline provide clear differentiation and room for expansion into other large disease areas, but the usual biotech uncertainties remain: regulatory decisions, clinical trial outcomes, competitive responses, and the eventual need for additional capital if commercialization does not ramp as expected. Overall, SRRK is best understood as a platform‑driven drug developer at an inflection point, with the next few years likely to be decisive for its trajectory.

NEWS

November 14, 2025 · 7:00 AM UTC

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Read more

November 12, 2025 · 4:15 PM UTC

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

October 23, 2025 · 8:00 AM UTC

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Read more

October 17, 2025 · 4:15 PM UTC

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

September 23, 2025 · 7:00 AM UTC

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Read more